Page 50 - Michael Breen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo (Reuters) - Johnson & Johnson said its single-dose vaccine was 72% effective in preventing COVID-19 in the United States but a lower rate of 66% was observed globally in the large trial conducted across three continents and against multiple variants. In the trial of nearly 44,000 volunteers, the level of protection against m...

LONDON: Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus. In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread. A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95% effective in preven...

5 Min Read (Reuters) - Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic. Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/File Photo In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the ...

Johnson & Johnson said on Friday (29 January) that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus. In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread. A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95% effective in p...

5 Min Read (Reuters) - Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic. In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread. The data showed that the vaccine’s effect on the South Africa variant was diminished compared to the unaltered virus, bu...